Company intelligence / Profile preview

Sentien Biotechnologies

Lexington, Massachusetts, United Statesmscrf.org ↗

Ownership: Private
Development stage: Phase 2

Overview

Completed enrollment of first cohort in Phase 1/2 study of SBI-101 for treatment of severe COVID-19. The company is developing novel approaches to cell therapy with a focus on controlled delivery of MSC secreted factors[2][8].

Therapeutic areas: ImmunologyInfectious DiseasesNephrology
Modalities: Cell therapyMesenchymal Stromal Cells (MSCs)
Industry: Biotech

Drug pipeline

1 asset

SBI-101

Partnerships

Biomedical Advanced Research and Development Authority (BARDA)Maryland Stem Cell Research Fund (MSCRF)

Beyond the preview

Go deeper on Sentien Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sentien Biotechnologies.

Explore the full profile